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Abstract 
Background: Recently the International Agency for Research on Cancer (IARC) Programme for 
the Evaluation of Carcinogenic Risks to Humans has been criticized for several of its 
evaluations, and also the approach used to perform these evaluations. Some critics have claimed 
that IARC Working Groups’ failures to recognize study weaknesses and biases of Working 
Group members have led to inappropriate classification of a number of agents as carcinogenic to 
humans.  
Objectives: The authors of this paper are scientists from various disciplines relevant to the 
identification and hazard evaluation of human carcinogens. We have examined here criticisms of 
the IARC classification process to determine the validity of these concerns. We review the 
history of IARC evaluations and describe how the IARC evaluations are performed.  
Discussion: We conclude that these recent criticisms are unconvincing. The procedures 
employed by IARC to assemble Working Groups of scientists from the various discipline and the 
techniques followed to review the literature and perform hazard assessment of various agents 
provide a balanced evaluation and an appropriate indication of the weight of the evidence. Some 
disagreement by individual scientists to some evaluations is not evidence of process failure.  The 
review process has been modified over time and will undoubtedly be altered in the future to 
improve the process. Any process can in theory be improved, and we would support continued 
review and improvement of the IARC processes. This does not mean, however, that the current 
procedures are flawed.  
Conclusions: The IARC Monographs have made, and continue to make, major contributions to 
the scientific underpinning for societal actions to improve the public’s health. 
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Introduction 
Important advances in human health have come from the recognition of health hazards and the 
development of policy actions to address them (Brownson et al. 2009; Espina et al. 2013; Samet 
2000). Government and non-governmental organizations use expert panels to review the 
scientific literature and to assess its relevance to public health policies. Scientific experts are 
charged with reviewing the quality and quantity of the scientific evidence and providing 
scientific interpretations of the evidence that underpin a range of health policy decisions.  
The IARC Monographs on the Evaluation of Carcinogenic Risks to Humans of the International 
Agency for Research on Cancer (IARC) are a prominent example of such an expert review 
process. The goal of the Monograph Programme is to assess carcinogenic hazards from 
occupational, environmental, and lifestyle exposures and agents, thus providing an essential step 
in the societal decision-making process to identify and then control carcinogenic hazards. For 
these evaluations, IARC assembles groups of scientists with a range of relevant scientific 
expertise (called “Working Groups”) to review and assess the quality and strength of evidence 
from informative publications and perform a hazard evaluation to assess the likelihood that the 
agents of concern pose a cancer hazard to humans (Tomatis 1976). IARC has used this approach 
for four decades since the first Monograph in 1972 ([Anonymous] 1972). Although widely 
accepted internationally, there have been criticisms of the classification of particular agents in 
the past, and more recent criticisms have been directed at the general approach adopted by IARC 
for such evaluations ([Anonymous] 2013; Boffetta 2007; Boffetta et al. 2009; Ioannidis 2005; 
Kabat 2012; McLaughlin et al. 2010; McLaughlin et al. 2011). 
The Monographs are widely used and referenced by governments, organizations, and the public 
around the world, therefore it is critical that Working Group conclusions be clear and 
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transparent. In addition to the actual evaluation, a major contribution of the Monographs is the 
assembly of relevant literature and its dissemination to the public. We recognize that no system 
of evaluation is perfect. It is important to foster continuing improvement of the methods used by 
IARC and other bodies that review scientific evidence. The IARC process itself has been 
modified from time to time (e.g., addition of specific evaluation of mechanistic data and greater 
use of formal meta-analyses and data pooling approaches). Indeed, as recently as April, 2014 
IARC Monographs program has been a subject of a review by the Advisory Group to 
recommend Priorities for IARC Monographs during 2015-2019 (Straif et al. 2014). The 
Advisory Group has made a number of recommendations on further improvements in the 
Monographs process, specifically related to conflict of interest, transparency, and the use of the 
systematic review procedures in data gathering and evaluation. Thus, possible changes to the 
process are periodically considered by IARC governing groups (Scientific Council and 
Governing Council) and Advisory Groups. 
In the current paper, we focus on current IARC processes and practices, since these have been 
the focus of recent criticisms. The authors of this paper are scientists from a wide range of 
disciplines who are involved in designing and conducting studies that provide data used in 
hazard evaluations, such as those performed by IARC. Many (but not all) of us have served on 
IARC Monograph Working Groups, but none are current IARC staff. We first discuss the history 
of IARC, and describe how the IARC evaluations are performed in order to foster evidence-
based policy. We then describe why unbiased evaluations, based on the evidence and free of 
conflicts of interest, are necessary for public health decision-making. Finally, we consider the 
recent criticisms of the IARC approach.  
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The IARC Monographs 
History of the IARC Monographs 
Shortly after IARC’s establishment, its parent entity, the World Health Organization (WHO), 
asked IARC to prepare a list of agents known to cause cancer in humans. IARC recognized the 
need for a systematic process to determine which agents should be listed. Such a process was 
launched in 1972 by Lorenzo Tomatis, then Chief of the Division of Carcinogenicity of IARC 
(Tomatis 1976). IARC is funded by the governments of 24 countries that have decided to 
become members, in addition to competitive grants from funding agencies. The IARC 
Monograph Programme is mainly funded by the US National Cancer Institute through a 
renewable grant subject to peer review of the Programme. Other sources of external funding 
have included the European Commission Directorate-General of Employment, Social Affairs and 
Equal Opportunities, the U.S. National Institute of Environmental Health Sciences, and the U.S. 
Environmental Protection Agency. 
The IARC process antedates current systematic review methods, but anticipated some of them, 
e.g. with regards to transparent literature identification. In the IARC process, agents are assessed 
for carcinogenic hazard and assigned to one of five categories, ranging from carcinogenic to 
humans to probably not carcinogenic to humans (Appendix 1). The classification categories are 
described in the preamble to the Monographs 
(http://monographs.iarc.fr/ENG/Monographs/PDFs/). Carcinogenic hazard identification refers to 
an assessment of whether an agent causes cancer. Hazard identification does not predict the 
magnitude of cancer risks under specific conditions; this can be determined only with 
appropriate exposure-response information (National Research Council 2009). 
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The IARC Monograph Process 
The process for the preparation of an IARC Monograph is clearly described in the Preamble 
which is published as part of each Monograph ([Anonymous] 2014b). It starts with the 
nomination of candidate agents. Nominations come from national regulatory agencies, scientists 
and stakeholders, including public health professionals, experts in environmental or occupational 
hygiene, industry representatives, and private citizens. It is important to note that anyone 
(including private citizens) can participate in the nomination process. The Monograph 
Programme convenes meetings of special Advisory Groups (AG), composed of external 
scientists that possess a broad range of relevant professional skills, to review agents nominated 
for evaluation and to suggest IARC priorities for such reviews (Ward et al. 2010). 
Announcements of a review are made on the IARC website 
(http://monographs.iarc.fr/ENG/Publications/internrep/08-001.pdf). For example, in 2014 IARC 
sought nominations for agents to be evaluated in 2015-2019. An AG reviewed the nominated 
agents and exposures, added several new ones, and discussed the priorities for each.  
The IARC staff make the final selection of agents for review by taking into account the 
prevalence and intensity of exposure (of both occupational groups and the general population) 
and availability of sufficient literature for an evaluation of carcinogenicity, as well as advice 
from the AG. The large majority of evaluations concern specific compounds, but there are also 
monographs on various occupations or industries, e.g. aluminum production, insecticide 
applicators, firefighters, leather goods manufacture, leather tanning and processing, welding, 
painter, petroleum refining, and pulp and paper manufacture.  Some individual exposures that 
occur in these settings have also been evaluated.  
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The next step is the selection of members of the Working Group (WG). This is made by IARC 
staff who review the literature to identify Working Group candidates and specialists in relevant 
areas of expertise; they also seek names of possible candidates from the scientific community 
and advisory groups. The list of potential members, including disclosure of relevant conflicts of 
interest, is posted on the IARC website before the WG is convened and anyone can send 
comments. Members are typically scientists who have conducted research relevant to the agent 
under review, but not necessarily on the specific agent. Selection procedures are evaluated yearly 
by the Scientific and the Governing Councils. The IARC Section of Monographs also has an 
external Advisory Board made of independent scientists that periodically peer-reviews its 
activities. In addition to Working Group members, invited specialists, representatives of health 
agencies, stakeholder observers, and the IARC Secretariat also attend meetings. 
The responsibility of the Working Group is to review the literature before the Monograph 
meeting, discuss the literature at the meeting, and then classify whether an agent is carcinogenic 
to humans, probably carcinogen, possibly carcinogenic, not classifiable as to its carcinogenicity 
to humans, or probably not carcinogenic to humans (see Appendix 1).  Working Group members 
are also responsible for writing each IARC Monograph, which must both review the literature 
and explain why the Working Group came to their specific conclusions. 
The procedures used to evaluate the scientific evidence are also described in the Preamble to the 
Monographs and on the IARC website (monographs.iarc.fr). It is important to stress that only 
Working Group members conduct the actual evaluation (Wild and Cogliano 2011; Wild and 
Straif 2011). IARC staff facilitate the evaluation process and ensure that the procedures 
described in the Preamble are followed; however, they do not determine the outcomes.  
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IARC assessments of carcinogenicity are based on, and necessarily limited to, scientific evidence 
available at the time of the review. The evidence comes from epidemiologic studies, animal 
bioassays, pharmacokinetic/mechanistic experiments, and surveys of human exposure. The aim 
is to include all relevant papers on cancer in humans and experimental animals that have been 
published, or accepted for publication, in peer-reviewed scientific journals, and also any publicly 
available government or agency documents that provide data on the circumstances and extent of 
human exposure. To this end, the search of the literature takes a comprehensive approach.  
Papers that are found not to provide useful evidence can be excluded later in the process. IARC 
staff first use previous IARC Monographs (if available), database searches using relevant text 
strings, and contact with investigators in the field to identify potentially relevant material.  Thus, 
the initial assembly of the literature is performed by individuals who are not engaged in the 
actual evaluation. Working Group members are then assigned various writing tasks and they are 
instructed to perform their own literature searches to identify any further papers that might have 
been missed.  In addition, all of the papers assembled by IARC are made available to the full 
Working Group before they meet, and any member can recommend other papers not identified, 
which they think should be considered. Finally, papers can be recommended by stakeholder 
representatives before or during the Working Group meeting.  
At the meeting of the Working Group, the assembled documents are reviewed by discipline-
related subgroups, which review and summarize them. However, any member of the Working 
Group has access to all of the assembled literature. The summaries are distributed to all 
subgroups, and information from all disciplines is discussed in plenary sessions prior to 
assigning the agents to a specific carcinogenicity category.  
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Because new findings continually emerge in the literature, agents are reconsidered when IARC 
and IARC Advisory Groups judge that there is sufficient additional information that might alter a 
previous evaluation. Thus, conclusions regarding human carcinogenicity of particular substances 
may change as new evidence becomes available. For some agents, this re-evaluation has resulted 
in progression toward greater certainty regarding their human carcinogenicity, whereas for others 
the progress has been moved toward less certainty. Such movements are expected in an open, 
transparent, and evidence-based process. A comprehensive update of all Group 1 carcinogens 
was recently accomplished in Volume 100 A through F 
(http://monographs.iarc.fr/ENG/Classification/). 
Usually, several agents are evaluated in a single meeting lasting more than one week. The 
Working Group members after discussing the evidence fully, follow the published IARC 
procedures for combining information from epidemiologic studies and bioassay to arrive at a 
preliminary classification ([Anonymous] 2014b).  Mechanistic data are then considered to 
determine if they warrant a change from this preliminary classification.  The Working Group 
then votes on the final determination. Many votes are unanimous, but on occasion some 
reviewers may favour a higher or lower ranking than the majority. When there is dissent, 
alternative interpretations and their underlying reasoning are sometimes reported in the rationale 
for the evaluation if the dissenters feel their point of view is not sufficiently addressed in the 
monograph.    
Consideration of the totality of the evidence 
IARC Working Groups make every effort to provide full and transparent documentation of what 
evidence was assembled, how it was evaluated, and which papers were most important for the 
hazard evaluation. Consequently, the monographs are often quite lengthy with many evidence 
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tables (see, for example, the recent Monograph on Trichloroethylene ([Anonymous] 2014a)). 
Evaluations involve consideration of all of the known relevant evidence from epidemiologic, 
animal, pharmacokinetic/mechanistic, and exposure studies to assess cancer hazard in humans. 
Information on human exposure is not formally graded as part of the overall assessment of 
carcinogenic hazard; however, these data make a critical contribution to the process by 
characterizing the timing, duration, and levels of exposure in the population, and in evaluating 
the quality of the exposure assessment in epidemiologic studies.  
Doubts and criticisms have sometimes been expressed about the relative weights attributed to 
evidence from  individual disciplines to the assessment of cancer hazards to humans; however,  
each provides important evidence toward the overall evaluation of causality according to the 
Bradford Hill considerations (Hill 1965). Because the totality of the evidence is considered, 
deficiencies in one discipline are often offset by strengths in another. For example, 
epidemiologic studies may focus on population-relevant exposures, whereas findings from 
animal experiments usually involve higher exposures but are less susceptible to confounding.   
Long-term animal bioassays and mechanistic studies provide critical information on the capacity 
of an agent to produce cancer in mammalian systems, including humans, and to contribute to 
decisions that would lead to better protection of human health. Bioassays are the backbone of 
regulatory science, because they provide the opportunity to rigorously evaluate potential hazards 
before there is widespread human exposure. Bioassays and mechanistic studies are sometimes 
criticized for employing exposure routes and doses that in most instances humans would not 
experience, although experimental dose categories sometimes approach exposure levels found in 
occupational situations. There is evidence that carcinogenicity in human and animal studies is 
often concordant, although data may differ as to the affected cancer site (Haseman 2000; 
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Maronpot et al. 2004; Tomatis 2002). A major effort to evaluate the concordance between animal 
and human results is currently underway; two Working Group were convened at IARC in 2012 
and a systematic evaluation of the correspondence between human and animal data was 
undertaken (no report is publicly available yet). 
Criticisms of the IARC process 
IARC Monographs are widely used to identify potential carcinogenic hazards to humans and 
serve as reference documents summarizing the literature on many different agents. In recent 
years, however, individuals have criticized both the classification of individual agents as well as 
the general evaluative approach ([Anonymous] 2013; Boffetta 2007; Boffetta et al. 2009; Kabat 
2012; McLaughlin et al. 2010; McLaughlin et al. 2011). We discuss four of these criticisms 
below.  
Criticisms of epidemiology  
Some of the criticisms of the IARC process occur in the context of more general criticisms of 
epidemiology as a science (Boffetta 2007; Kabat 2008); these have been discussed in detail in a 
recent paper (Blair et al. 2009). Potential methodological weaknesses for observational 
epidemiologic studies are well recognized and can be found in any epidemiologic textbook 
(Checkoway et al. 2004; Rothman et al. 2008). Most studies are subject to one or more 
methodological limitations, but this does not necessarily invalidate their findings (Blair et al. 
2009). In fact, the value of epidemiologic studies has been shown in identifying in multiple 
studies a number of well-established human carcinogens, including tobacco, asbestos, benzene, 
hexavalent chromium, and some viruses. Some critics also argue that small or non-existent 
health risks are unjustifiably highlighted and hyped by researchers who have a vested interest in 
continued research funding and the need to publish to benefit their careers (Boffetta et al. 2008; 
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Kabat 2008; McLaughlin et al. 2010; McLaughlin et al. 2011; Taubes 1995). However, such 
over-stated results are unlikely to exert much of an influence in a Monograph, because IARC 
evaluations are based on the totality of the evidence. The problem would have to occur in 
multiple studies and the Working Group would have to be unable to identify it, or be unwilling to 
weigh such studies appropriately. Incorrect positive conclusions regarding carcinogenicity may 
also occur in reviews of multiple studies because of publication bias, which may selectively 
populate the literature with only “positive” findings.  However, once a topic is recognized as 
scientifically important, reports on relevant studies will be published regardless of the findings, 
so publication bias is mainly a concern for newly arising issues.  To evaluate the potential for 
publication bias, Working Groups consider whether stronger, negative studies (both in terms of 
design and sample size) have emerged after publication of an initial cluster of smaller and/or 
weaker positive studies.  Funnel plots help in the assessment of bias relating to sample size and 
publication bias (Borenstein et al. 2009).  In contrast, there are no established statistical 
techniques to clearly characterize strength of design. 
One of the distinctive features of epidemiology is that criticism and self-criticism are firmly 
embedded in the discipline. A great deal of work has been done on developing methods for 
critical appraisal (Elwood 2007) and for assessing the likely strength and direction of possible 
biases (Rothman et al. 2008). Epidemiologists and other members on Working Groups routinely 
use various approaches to assess possible bias in study design and analysis when weighing the 
strengths of different studies. 
The issue of false positives 
Epidemiology specifically has been criticized for a tendency to produce false positive results 
(i.e., individual study associations not borne out by the weight of the evidence), or to 
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preferentially report positive findings over negative or inconclusive findings (i.e., publication 
bias) (Boffetta et al. 2008, 2009; Ioannidis 2005; Kabat 2012; McLaughlin and Tarone 2013). 
This criticism has been most often applied to potential false positives from individual studies, but 
it has been inferred that this problem may also apply to overall hazard evaluations which use 
findings from multiple studies. We will consider each of these issues in turn. 
False positive findings may occur by chance, particularly when many combinations of exposures 
and health outcomes have been examined in a single study without strong prior expectations of 
association; this happens often, for example, in GWAS studies where thousands of gene-disease 
associations are evaluated.  Chance, of course, operates in all disciplines and in both 
observational and experimental studies. However, there are well-known statistical techniques to 
reduce the probability of declaring chance findings as “positive” (Rothman et al. 2008). 
Independent replication, however, is the most convincing way of checking for “chance” findings, 
and hazard evaluations such as those conducted by IARC Working Groups rely heavily on 
reproducibility in independent studies and interpret data following Bradford Hill principles (Hill 
1965).  
False negatives are more difficult to address, and perhaps they occur more frequently than false 
positives because of low statistical power, non-differential misclassification of exposure and/or 
outcome, and incomplete follow-up, which tends to reduce the observed difference in risk 
between the exposed and non-exposed populations (Ahlbom et al. 1990; Blair et al. 2009; 
Grandjean 2005; Rothman et al. 2008). A new positive association stimulates research, while 
studies finding no associations tend to stifle further work.  
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There are difficulties in conducting epidemiologic studies of agents that are relatively “weak” 
carcinogens, or for stronger carcinogens where exposure is very low because bias and 
confounding can obscure weak positive associations (Macmahon et al. 1981).  In general, weak 
carcinogens and low levels of exposure result in a smaller “signal to noise” ratio making the real 
signal more difficult to detect. Although the identification of small relative risks to humans poses 
special challenges to scientific research, the refinement of study designs, improvements in 
methods of exposure assessment and the use of biomarkers have helped to address the problems 
(e.g., the newer studies on the effects of air pollution, and the growth in opportunities to examine 
gene- and environment interactions) (Gallo et al. 2011).  In some situations, there is less of a 
problem. For example, in occupational studies, exposures and relative risks may be higher, while 
differences in lifestyle factors between different groups of workers are smaller (Checkoway et al. 
2004), thus any confounding by non-occupational factors is likely to be weak, even from potent 
causes of cancer, such as cigarette smoking (Siemiatycki et al. 1988). Of course, the 
interpretation of such studies is enhanced when there is supporting evidence from bioassays 
and/or mechanistic studies. 
False positive and false negative findings in individual studies may arise by chance, or bias, 
including bias due to confounding (Rothman et al. 2008). However, the evaluation of multiple, 
independent epidemiologic studies, from various geographic locations, involving a variety of 
study designs, as well as evidence from experimental studies, reduces the possibility that false 
positive findings from any individual study influences the overall evaluation process. Some 
studies may have greater influence than others because of methodological strengths and/or large 
sample size. The use of information from a variety of study designs reduces the likelihood of 
false positive evaluations, because it is unlikely that the same biases will occur in multiple 
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studies based on different populations under different study designs. Moreover, apparently 
conflicting results from epidemiologic studies do not necessarily indicate that some are false 
positive or false negative.  This might, for example, reflect differences in levels of exposure or 
susceptibility to the effects of exposure (effect modification). Finally, judgment by the Working 
Group is not based exclusively on epidemiologic studies, but usually also on results from 
laboratory and mechanistic studies that provide further evidence and biological coherence. For 
the Monographs that evaluate carcinogenic hazards associated with specific occupations or 
industries, the exposures of interest usually involve a complex mixture of chemicals. For these 
evaluations, most information comes from epidemiologic studies, although exposures to 
individual agents occurring at these workplaces may have been evaluated in experimental 
studies.  
 Discontent with IARC Monograph processes  
The IARC Monograph evaluation process has been criticized and it has been alleged that “a 
number of scientists with direct experience of IARC have felt compelled to dissociate themselves 
from the agency’s approach to evaluating carcinogenic hazards.”(Kabat 2012) This is a serious 
charge. However, the authors of this claim provide no evidence to support the charge that a 
“number of scientists” have dissociated themselves from the process, nor has there been any 
indication of how many scientists have taken this step, or for what reason. In science, we expect 
sweeping statements such this to be appropriately documented. We have not been able to identify 
any credible support for this contention.   
There is an IARC Governing Council and a Scientific Council to provide oversight and guidance 
to the agency. The Governing Council represents the participating states and sets general IARC 
policy.  It appoints the IARC Director and members of the Scientific Council.  The latter are 
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independent scientists who are selected to provide scientific expertise and not as representatives 
of the member states. They serve for four years and serve without pay.  The voting members of 
Monograph Working Groups are not employed by IARC and they perform this task without 
financial compensation (see above). There have been 111 volumes, including six separate 
documents under Volume 100, and three Supplements.  Over the years, as the number of 
publications for each agent to be evaluated increased, the size of Working Groups has increased. 
Early in the process they were sometimes as small as 10, but now they sometimes include as 
many as 30 scientists.  We estimate that over the entire Monograph series approximately 1500 
scientists have served as Working Group members, and of course many scientists have also 
served on the Advisory Groups, Scientific Council and Governing Council. Thus, if even a small 
percentage of these scientists were disenchanted with the IARC process, it would result in a 
considerable number of such individuals and should be easy to document.  To be taken seriously 
the “dissociation” criticism needs to be supported by documented information describing the 
number scientists who have taken this action. 
Criticisms of specific evaluations 
Some criticisms of the IARC process relate to specific agents, where it is asserted that the hazard 
evaluations of category 2B, 2A, or 1 are not supported by the scientific literature (Boffetta 2007). 
In the 111 volumes of the Monographs produced over the four decades since 1971, 970 agents 
have been considered, 114 (12%) have been classified as carcinogenic to humans (Group 1), 69 
(7%) as probably carcinogenic (Group 2A), 283 (29%) as possibly carcinogenic (Group 2B), 504 
(52%) as not classifiable regarding their carcinogenicity (Group 3), and 1 (<1%) as probably not 
carcinogenic to humans (Group 4).  Thus, even for this highly selected group of agents (i.e., 
those selected for evaluation because there was some concern that they might be carcinogenic), 
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more than one half were ‘not classifiable’ or ‘probably not carcinogenic’, and a further 29% were 
placed into the category of possibly carcinogenic to humans.  This distribution, based on nearly 
1000 evaluations, in which fewer than one in five agents were classified as carcinogenic, or 
probably carcinogenic, to humans does not support a conclusion that the process is heavily 
biased towards classifying agents as carcinogenic (Boffetta 2007; Boffetta et al. 2009; Kabat 
2012). 
The Monographs for formaldehyde, coffee, DDT, and radiofrequency electromagnetic radiation 
have been cited as examples of problematic evaluations by some (Kabat 2012) (note that, among 
these, only formaldehyde was classified as known to be carcinogenic to humans (Group 1) by an 
IARC Working Group). These are important agents. However, to accept the charge that IARC 
evaluations are fundamentally biased, one has to assume that the scientists who were members of 
the Working Groups were incapable of appropriately evaluating weaknesses in the data, or that 
they distorted the evaluative process because of personal biases.  In our experience neither of 
these assertions is correct. Dissent among scientists is not unusual in any area of science. It is a 
strength of the scientific process. The IARC process capitalizes on this by bringing scientists 
from different disciplines together in one room to evaluate the literature and to reach a reasoned 
conclusion.  Differences of opinion occur among Working Group members. These differences, 
however, typically involve disputes related to assignment to adjacent classification categories. It 
is instructive that there are no instances in which a carcinogen classified at the Group 1 level by 
one Working Group has been reversed by another. The recent review of all Group 1 agents for 
Volume 100 provided ample opportunity to reverse such previous classifications, but none 
occurred. Every scientist could probably name a substance that has been reviewed by IARC that 
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they might personally place in a different category from that assigned by the Working Group, but 
this is one opinion against the collective wisdom and process of the Working Group, 
Criticisms of the composition of the Working Groups 
The composition of the Working Groups has also been criticized (Erren 2011; McLaughlin et al. 
2010; McLaughlin et al. 2011); it has been argued that members of the Working Groups who 
have conducted research on the agents under evaluation have a vested interest in advancing their 
own research results in the deliberations. This criticism has been addressed directly by Wild et 
al. (Wild and Cogliano 2011; Wild and Straif 2011) from IARC, and we know of no evidence to 
support this contention.  Even if some scientists on the Working Group have performed research 
on some of the agents being considered, they make up a minority of the Working Group because 
several agents are usually evaluated in a single meeting, so the number of Working Group 
members who have conducted research on any one agent is typically small. Our experience has 
been that having some scientists who are knowledgeable about the studies of the agent under 
evaluation (and can therefore answer technical queries) and others from different, but related, 
fields provides a knowledgeable and balanced mix of scientific backgrounds for a thoughtful 
evaluation of the literature.  
Working Group members do not receive any fee for their work, but are paid travel expenses, and 
there is some prestige associated with service on an IARC Monograph. However, most scientists 
asked to serve on IARC Working Groups have already achieved some measure of scientific 
stature, and there is no reason why this should bias their evaluation in one direction of the other. 
In addition, IARC strictly requires that any conflict of interests are divulged, and does not allow 
those with conflicts of interest to serve on Working Groups, although non-voting observers who 
may conflict of interest are able to attend the Working Group meetings. 
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Conclusions 
For over four decades the IARC Monograph Programme has provided evaluations of cancer 
hazards to humans from many different exposures and agents.  These are often the first 
evaluations of new and emerging threats to public health and, consequently, are subject to 
intense scrutiny.  Although these evaluations are widely respected and used by many 
organizations, institutions, companies, and government agencies to improve the public’s health, 
IARC has recently been subject to criticism over conclusions on specific agents, the process that 
leads to such conclusions, and membership of the Working Groups.  Debate and criticism 
facilitate self-correction and a check on the validity in science.  We are concerned, however, that 
the criticisms expressed by a vocal minority regarding the evaluations of a few agents may 
promote the denigration of a process that has served the public and public health well for many 
decades for reasons which are not supported by data.  
There has been very broad involvement of the scientific community in the IARC Monograph 
Programme through participation in the Working Groups and service on the IARC Governing 
and Scientific Councils and ad hoc Advisory Board for the Monograph Programme.  The long 
list of scientists who are coauthors of this paper attests to the strong support that IARC has in the 
scientific community. Many exposures that IARC has evaluated have also been independently 
evaluated by other institutions, e.g., the U.S. National Toxicology Program; U.S. Environmental  
Protection Agency; National Academy of Sciences; the ACGIH TLV/BEI threshold limit values; 
the Nordic Expert Group for Criteria Documentation of Health Risks from Chemicals 
(http://www.av.se/arkiv/neg/?AspxAutoDetectCookieSupport=1); Institute of Occupational 
Medicine (IOM), Edinburgh, Scotland; WCRF/AIRC Expert Reports; European Chemicals 
Agency (https://echa.europa.eu); Swedish Criteria Group for Occupational Standards 
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(https:gupea.ub.gu.se/handle/2077/34986); California Office of Environmental Hazard 
Assessment (http://oehha.ca.gov/prop65/background/p65plain.html); Bureau of Chemical Safety 
in Canada (http://www.hc-sc.gc.ca/ahc-asc/branch-dirgen/hpfb-dgpsa/fd-da/bcs-bsc/index-
eng.php); Scientific Committee on Occupational Exposure Limits (SCOEL); European 
Commission, Employment, Social Affairs and Inclusion 
(http://ec.europa.eu/social/main.jsp?catId=148&langId=en&intPageId=684); European Food 
Safety Authority (EFSA) (http://www.efsa.europa.eu/en/search/doc/3132.pdf); and European 
Chemicals Agency (ECHA)(http://echa.europa.eu/), and assessments from these groups typically 
come to conclusions similar to those from IARC. This further indicates broad agreement within 
the scientific community regarding evidence on carcinogenicity in the scientific literature and 
expands the number of scientists who do not have a “vested interest”, but who have generally 
agreed with those conclusions.  
Disagreement with the conclusions in an IARC Monograph for an individual agent is not 
evidence for a failed or biased approach.  Some disagreement about the carcinogenic hazard of 
important agents seems inherent to the scientific enterprise and unavoidable at early stages of the 
hazard evaluation, where IARC usually operates. Because the evaluations are not, and should not 
be, static it is difficult to see how such assessments could be addressed any differently. 
Substances now universally recognized as human carcinogens (e.g., tobacco and asbestos) at one 
time went through a quite lengthy period of contentious debate (Michaels 2006, 2008). Any 
process can in theory be improved with fair and constructive criticism, and appropriate reviews 
may take place from time to time, and we would support continued review and improvement of 
the IARC processes. However, as a group of international scientists, we have looked carefully at 
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the recent charges of flaws and bias in the hazard evaluations by IARC Working Groups, and we 
have concluded that the recent criticisms are unfair and unconstructive.   
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Appendix 1: Classification categories for the Overall Evaluation for 
the IARC Monographs 
Group 1: The agent is carcinogenic to humans. 
This category is used when there is sufficient evidence of carcinogenicity in humans. 
Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in 
humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental 
animals and strong evidence in exposed humans that the agent acts through a relevant 
mechanism of carcinogenicity. 
Group 2. 
This category includes agents for which, at one extreme, the degree of evidence of 
carcinogenicity in humans is almost sufficient, as well as those for which, at the other extreme, 
there are no human data but for which there is evidence of carcinogenicity in experimental 
animals. Agents are assigned to either Group 2A (probably carcinogenic to humans) or Group 
2B (possibly carcinogenic to humans) on the basis of epidemiological and experimental evidence 
of carcinogenicity and mechanistic and other relevant data. The terms probably 
carcinogenic and possibly carcinogenic have no quantitative significance and are used simply as 
descriptors of different levels of evidence of human carcinogenicity, with probably 
carcinogenic signifying a higher level of evidence than possibly carcinogenic. 
Group 2A: The agent is probably carcinogenic to humans. 
This category is used when there is limited evidence of carcinogenicity in humans and sufficient 
evidence of carcinogenicity in experimental animals. In some cases, an agent may be classified in 
this category when there is inadequate evidence of carcinogenicity in humans and sufficient 
evidence of carcinogenicity in experimental animals and strong evidence that the carcinogenesis 
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is mediated by a mechanism that also operates in humans. Exceptionally, an agent may be 
classified in this category solely on the basis of limited evidence of carcinogenicity in humans. 
An agent may be assigned to this category if it clearly belongs, based on mechanistic 
considerations, to a class of agents for which one or more members have been classified in 
Group 1 or Group 2A. 
Group 2B: The agent is possibly carcinogenic to humans. 
This category is used for agents for which there is limited evidence of carcinogenicity in humans 
and less than sufficient evidence of carcinogenicity in experimental animals. It may also be used 
when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence 
of carcinogenicity in experimental animals. In some instances, an agent for which there 
is inadequate evidence of carcinogenicity in humans and less than sufficient evidence of 
carcinogenicity in experimental animals together with supporting evidence from mechanistic and 
other relevant data may be placed in this group. An agent may be classified in this category 
solely on the basis of strong evidence from mechanistic and other relevant data. 
Group 3: The agent is not classifiable as to its carcinogenicity to humans. 
This category is used most commonly for agents for which the evidence of carcinogenicity is 
inadequate in humans and inadequate or limited in experimental animals. 
Exceptionally, agents for which the evidence of carcinogenicity is inadequate in humans 
but sufficient in experimental animals may be placed in this category when there is strong 
evidence that the mechanism of carcinogenicity in experimental animals does not operate in 
humans. 
Agents that do not fall into any other group are also placed in this category. 
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An evaluation in Group 3 is not a determination of non-carcinogenicity or overall safety. It often 
means that further research is needed, especially when exposures are widespread or the cancer 
data are consistent with differing interpretations. 
Group 4: The agent is probably not carcinogenic to humans. 
This category is used for agents for which there is evidence suggesting lack of carcinogenicity in 
humans and in experimental animals. In some instances, agents for which there is inadequate 
evidence of carcinogenicity in humans but evidence suggesting lack of carcinogenicity in 
experimental animals, consistently and strongly supported by a broad range of mechanistic and 
other relevant data, may be classified in this group. 
